In The Lancet Infectious Diseases,
Alessandro Cassini and colleagues describe how they measured the health burden of five types of antibiotic-resistant infection (invasive and non-invasive) caused by eight bacteria with 16 resistance patterns in the EU and European Economic Area (EAA).
The estimates, for the 1st time presented as disability-adjusted life-years (DALYs), are truly shocking.
Evaluation of the burden of infectious diseases can be challenging because they occur at different time scales and are influenced by many factors (ie, demography, epidemiological setting, population ageing, and method of measurement).
Cassini and colleagues report the first attempt to quantify DALYs for other resistant infections.
By using this new method, their study adds to the evidence base on the burden of antimicrobial resistance and could have a crucial role in fighting such resistance. By providing for the first time DALY data for countries with a high burden of antimicrobial resistance, this study calls for increased political awareness of, and commitment to, antimicrobial resistance.
New strategies in the treatment of infections are therefore highly warranted, as this study confirms that antibiotic resistance (antimicrobial resistance, AMR) is emerging much more rapidly than originally thought. This resistance will increase over the coming years and decades because of the excessive use of traditional antibiotics in humans and animals.
Madam Therapeutics is developing SAAPs as a new class of antimicrobial agents are highly active against resistant bacteria and have a very favorable tolerance profile. Our SAAPs combine two characteristics essential for such new strategies: powerful killing of bacteria and limited likelihood of emerging resistance.